The influence of hepatic cirrhosis on th
β
Dr G. Kaiser; R. Ackermann; H. P. Gschwind; I. M. James; D. Sprengers; N. McInty
π
Article
π
1990
π
John Wiley and Sons
π
English
β 552 KB
The influence of hepatic disease on the pharmacokinetics of the new ACE inhibitor, benazepril hydrochloride, was evaluated in 12 male patients suffering from liver cirrhosis. The patients received a single oral 20 mg dose. The plasma concentrations and urinary excretion of unchanged benazepril and i